Headache News and Research

Latest Headache News and Research

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Epilepsy drug-switching study shows that using more ethical control groups could be the way forward for testing both drug efficacy and safety

5 Dec 2011

Study: 3D-TV may cause seizures in children and adolescents

Certain visual patterns and flashing images can provoke seizures in susceptible individuals, particularly among children and adolescents. Some media reports on the recent introduction of 3D-television sets suggest that this new technology may cause seizures in some viewers.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

In a development that could pave the way for treatment for rare neurological diseases and clues to more common ones, physician-scientists at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have secured a grant to establish a clinical site for the Network for Excellence in Neuroscience Clinical Trials.

2 Dec 2011

ACGME approves Cedars-Sinai's neurology residency training program

The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

30 Nov 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

Post traumatic stress disorder and concussion syndrome treatable three years after injury: Study

Research led by Dr. Paul Harch, Associate Clinical Professor of Medicine at LSU Health Sciences Center New Orleans, has found that treatment with hyperbaric oxygen nearly three years after injury significantly improved function and quality of life for veterans with traumatic brain injury and post-traumatic stress disorder.

29 Nov 2011

Suppressing mosquitoes - the only way of controlling dengue

There is no vaccine against dengue, an emerging tropical disease regularly also hitting tourists, so the only way of controlling it is by suppressing the mosquitoes transmitting the disease.

28 Nov 2011

Migraines and depression risk: Study finds link

According to a new Canadian study, people who get attacks of migraine may be at a higher risk for developing clinical depression.

27 Nov 2011

Acetaminophen over-use can lead to serious liver damage

Common pain and fever Acetaminophen (best known by the brand name Tylenol) taken over a long time can cause liver failure and death, according to a new study.

24 Nov 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011

Transcept receives FDA approval for Intermezzo to treat insomnia

The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Deep brain stimulation benefits highly treatment resistant patients with major depressive disorder

Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005.

18 Nov 2011

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

18 Nov 2011

Medicaid officials struggle with surge in long-term care needs

The company's naming of David J. McNichols comes as a consulting firm for the state is evaluating the current system of delivering care to Medicaid and PeachCare beneficiaries in Georgia. WellCare has part of that multibillion-dollar business, along with two other managed care companies. The state pays the three firms a total of more than $2.5 billion a year to serve the Medicaid and PeachCare populations.

18 Nov 2011

Headache News and Research

Latest Headache News and Research

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Study: 3D-TV may cause seizures in children and adolescents

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Baby boomers more likely to develop HCV

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

ACGME approves Cedars-Sinai's neurology residency training program

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Post traumatic stress disorder and concussion syndrome treatable three years after injury: Study

Suppressing mosquitoes - the only way of controlling dengue

Migraines and depression risk: Study finds link

Acetaminophen over-use can lead to serious liver damage

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Transcept receives FDA approval for Intermezzo to treat insomnia

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Deep brain stimulation benefits highly treatment resistant patients with major depressive disorder

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Medicaid officials struggle with surge in long-term care needs

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in